{
  "generated_at_pt": "01-27-2026 00:36",
  "buys": [
    {
      "ticker": "ABT",
      "company": "Abbott Laboratories",
      "signal": "BUY",
      "score": 23.25,
      "why": "Below slow SMA • Oversold • Bearish MACD",
      "price": 108.77,
      "price_str": "108.77",
      "rsi": 21.238619604143096,
      "pe": 29.239246,
      "market_cap": 189309714432.0,
      "pct_drop": -1.2567509347109294,
      "rsi_str": "21.2",
      "pe_str": "29.2",
      "market_cap_str": "189.3B",
      "dma200": 129.52640007019042,
      "dma50": 124.70879959106445,
      "dma200_str": "129.5",
      "dma50_str": "124.7",
      "trend_rationale": "Weak/Sideways Bearish Trend (ADX: 22.3)",
      "trend_dir": "bearish",
      "put": {
        "strike": 70.0,
        "expiration": "Feb 20, 2026",
        "exp_type": "MONTHLY",
        "weekly_available": true,
        "monthly_available": true,
        "premium": 0.38,
        "delta_percent": 35.644019490668384,
        "premium_percent": 0.34936103705065735,
        "metric_sum": 35.99338052771904
      },
      "news_summary": "Intuitive’s cardiac initiative includes valve repair, LAA closure.",
      "news": [
        {
          "headline": "Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact",
          "url": "https://finance.yahoo.com/news/evercore-isi-says-abbott-abt-214325952.html",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026.\n\nEvercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact\n\nCourtesy of Abbott Labs\n\nOn January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating. The firm acknowledged the recent stumbles that led to a quarterly miss and a more cautious outlook for the second half, but said the bigger picture has no"
        },
        {
          "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
          "url": "https://finance.yahoo.com/news/abbott-laboratories-abt-trending-stock-140003240.html",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.\n\nShares of this maker of infant formula, medical devices and drugs have returned -14% over the past month versus the Zacks S&P 500 composite's +0.2% change. The Zacks Medical - Products industry, to which Abbott belongs, has lost 8% over this period. Now the key question is: Where could the stock be headed in the"
        },
        {
          "headline": "3 Reasons to Buy This Dividend King After Its Steep Sell-Off",
          "url": "https://www.fool.com/investing/2026/01/26/3-reasons-to-buy-this-dividend-king-after-its-stee/",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Investors' reaction to this Dividend King's Q4 revenue miss was overdone.\n\nAbbott Laboratories (ABT +1.26%) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly 10%. As you probably figured out from that brief overview, investors didn't like the healthcare giant's Q4 update.\n\nHowever, Abbott has been a favorite for many income investors. The company is a member of the Dividend Kings, an elite group of "
        },
        {
          "headline": "Intuitive’s cardiac initiative includes valve repair, LAA closure",
          "url": "https://www.medtechdive.com/news/intuitive-Surgical-robotic-cardiac-surgery-indications/810474/",
          "sentiment": -0.05,
          "summary": "",
          "article_text": "Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback\n\nIntuitive Surgical on Monday provided more details about its new cardiac surgery initiative for the da Vinci 5 robot, including specifying nine procedures that received U.S. clearance.\n\nAmong those are mitral and tricuspid valve repair, mitral valve replacement, and left atrial appendage closure — procedures that comprise key businesses for heart device companies such as Boston Scientific, Abbott a"
        },
        {
          "headline": "Is Abbott’s January Pullback a Good Time to Buy?",
          "url": "https://www.marketbeat.com/originals/is-abbotts-january-pullback-a-good-time-to-buy/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "sentiment": 0.7,
          "summary": "Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.",
          "article_text": ""
        }
      ]
    }
  ],
  "sells": [],
  "all": [
    {
      "ticker": "ABT",
      "company": "Abbott Laboratories",
      "signal": "BUY",
      "score": 23.25,
      "why": "Below slow SMA • Oversold • Bearish MACD",
      "price": 108.77,
      "price_str": "108.77",
      "rsi": 21.238619604143096,
      "pe": 29.239246,
      "market_cap": 189309714432.0,
      "pct_drop": -1.2567509347109294,
      "rsi_str": "21.2",
      "pe_str": "29.2",
      "market_cap_str": "189.3B",
      "dma200": 129.52640007019042,
      "dma50": 124.70879959106445,
      "dma200_str": "129.5",
      "dma50_str": "124.7",
      "trend_rationale": "Weak/Sideways Bearish Trend (ADX: 22.3)",
      "trend_dir": "bearish",
      "put": {
        "strike": 70.0,
        "expiration": "Feb 20, 2026",
        "exp_type": "MONTHLY",
        "weekly_available": true,
        "monthly_available": true,
        "premium": 0.38,
        "delta_percent": 35.644019490668384,
        "premium_percent": 0.34936103705065735,
        "metric_sum": 35.99338052771904
      },
      "news_summary": "Intuitive’s cardiac initiative includes valve repair, LAA closure.",
      "news": [
        {
          "headline": "Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact",
          "url": "https://finance.yahoo.com/news/evercore-isi-says-abbott-abt-214325952.html",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026.\n\nEvercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact\n\nCourtesy of Abbott Labs\n\nOn January 23, Evercore ISI trimmed its price target on Abbott Laboratories (NYSE:ABT) to $138 from $144. However, it kept an Outperform rating. The firm acknowledged the recent stumbles that led to a quarterly miss and a more cautious outlook for the second half, but said the bigger picture has no"
        },
        {
          "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
          "url": "https://finance.yahoo.com/news/abbott-laboratories-abt-trending-stock-140003240.html",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.\n\nShares of this maker of infant formula, medical devices and drugs have returned -14% over the past month versus the Zacks S&P 500 composite's +0.2% change. The Zacks Medical - Products industry, to which Abbott belongs, has lost 8% over this period. Now the key question is: Where could the stock be headed in the"
        },
        {
          "headline": "3 Reasons to Buy This Dividend King After Its Steep Sell-Off",
          "url": "https://www.fool.com/investing/2026/01/26/3-reasons-to-buy-this-dividend-king-after-its-stee/",
          "sentiment": 0.0,
          "summary": "",
          "article_text": "Investors' reaction to this Dividend King's Q4 revenue miss was overdone.\n\nAbbott Laboratories (ABT +1.26%) announced its 2025 fourth-quarter and full-year results before the market opened on Thursday, Jan. 22, 2026. And its shares promptly plunged nearly 10%. As you probably figured out from that brief overview, investors didn't like the healthcare giant's Q4 update.\n\nHowever, Abbott has been a favorite for many income investors. The company is a member of the Dividend Kings, an elite group of "
        },
        {
          "headline": "Intuitive’s cardiac initiative includes valve repair, LAA closure",
          "url": "https://www.medtechdive.com/news/intuitive-Surgical-robotic-cardiac-surgery-indications/810474/",
          "sentiment": -0.05,
          "summary": "",
          "article_text": "Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback\n\nIntuitive Surgical on Monday provided more details about its new cardiac surgery initiative for the da Vinci 5 robot, including specifying nine procedures that received U.S. clearance.\n\nAmong those are mitral and tricuspid valve repair, mitral valve replacement, and left atrial appendage closure — procedures that comprise key businesses for heart device companies such as Boston Scientific, Abbott a"
        },
        {
          "headline": "Is Abbott’s January Pullback a Good Time to Buy?",
          "url": "https://www.marketbeat.com/originals/is-abbotts-january-pullback-a-good-time-to-buy/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "sentiment": 0.7,
          "summary": "Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.",
          "article_text": ""
        }
      ]
    }
  ]
}